According to VentiRx Pharmaceuticals, a Phase I clinical trial of its VTX-1463 nasal spray for the treatment of allergic rhinitis demonstrated that once-weekly administration of the drug produced a significantly greater reduction in total nasal symptom scores than did a placebo. VTX-1463 is a selective toll-like receptor 8 (TLR8) agonist. Read the company’s press release.
